We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ViGeneron GmbH has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. have announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.